StockData
TEVANYSEPharmaceutical PreparationsFiscal year ends December 31

TEVA PHARMACEUTICAL INDUSTRIES LTD

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$41.31−0.19 (-0.46%)

Close on Oct 19, 2026

Market cap
$48.13B
P/E (TTM)
68.9
Dividend yield
–

Teva Pharmaceutical Industries statistics

Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison

Valuation

MeasureTeva Pharmaceutical IndustriesIndustry median
Market Cap$48.14B$197.05M
Enterprise Value$48.99B$106.56M
PE Ratio68.8520.52
PS Ratio3.413.93
PB Ratio6.212.14
P/FCF Ratio35.7118.25
P/OCF Ratio25.3613.78

Enterprise value

MeasureTeva Pharmaceutical IndustriesIndustry median
EV / Sales3.472.69
EV / EBITDA18.9014.86
EV / EBIT30.5619.00
EV / FCF36.3421.02

Income (trailing twelve months)

MeasureTeva Pharmaceutical IndustriesIndustry median
Revenue$14.10B$57.94M
Gross Profit$9.09B$90.47M
Operating Income$1.60B-$21.44M
Pretax Income$708.00M-$14.45M
Net Income$706.00M-$22.46M
EBITDA$2.59B-$16.91M
EPS (Diluted)$0.60-$0.83

Margins

MeasureTeva Pharmaceutical IndustriesIndustry median
Gross Margin64.4%52.3%
Operating Margin11.4%-44.5%
Pretax Margin5.02%-13.0%
Profit Margin5.01%-39.2%
EBITDA Margin18.4%-31.3%
FCF Margin9.56%-8.85%

Returns

MeasureTeva Pharmaceutical IndustriesIndustry median
Return on Equity (ROE)9.68%-53.1%
Return on Assets (ROA)1.77%-41.0%
Return on Invested Capital (ROIC)23.0%-32.0%
Return on Capital Employed (ROCE)6.62%-37.8%

Growth

MeasureTeva Pharmaceutical IndustriesIndustry median
Revenue Growth (YoY)-15.2%6.01%
FCF Growth (YoY)51.5%2.34%
Revenue Growth (3Y CAGR)4.96%2.25%
Revenue Growth (5Y CAGR)0.71%6.42%

Balance sheet

MeasureTeva Pharmaceutical IndustriesIndustry median
Cash & Short-Term Investments$3.66B$62.42M
Total Debt$4.50B$120.13M
Net Cash (Debt)-$845.00M$15.68M
Net Cash Per Share-$0.73$0.65
Equity (Book Value)$7.75B$48.79M
Book Value Per Share$6.65$1.36
Tangible Book Value-$11.53B$23.06M
Working Capital-$1.89B$75.77M

Financial position

MeasureTeva Pharmaceutical IndustriesIndustry median
Current Ratio0.883.30
Quick Ratio0.462.39
Debt / Equity0.580.51
Debt / EBITDA1.743.35
Debt / FCF3.345.05
Net Debt / EBITDA0.332.22

Cash flow (trailing twelve months)

MeasureTeva Pharmaceutical IndustriesIndustry median
Operating Cash Flow$1.90B-$12.35M
Capital Expenditures-$550.00M-$1.06M
Free Cash Flow$1.35B-$20.28M
FCF Per Share$1.16-$0.41

Efficiency

MeasureTeva Pharmaceutical IndustriesIndustry median
Asset Turnover0.350.38
Inventory Turnover2.452.67
Revenue Per Employee$415.43K$398.96K
Profits Per Employee$20.80K-$732.08K
Employee Count33,95073

Dividends and yields

MeasureTeva Pharmaceutical IndustriesIndustry median
Earnings Yield1.47%-21.2%
FCF Yield2.80%-7.64%

Shares

MeasureTeva Pharmaceutical IndustriesIndustry median
Shares Outstanding1,165,300,00059,128,900
Shares Change (YoY)2.03%11.1%
Float1,160,260,00048,744,500
Shares Held by Insiders0.43%11.8%

Taxes

MeasureTeva Pharmaceutical IndustriesIndustry median
Income Tax$12.00M$91.50K
Effective Tax Rate1.69%20.6%

Scores

MeasureTeva Pharmaceutical IndustriesIndustry median
Graham Number$9.48$17.36
Graham Upside-77.1%-45.5%
Altman Z-Score0.840.10
Piotroski F-Score84
Beneish M-Score-2.37-2.62

Calculated by StockData from Teva Pharmaceutical Industries's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.